News and Media
News and Media
Ordinary General Meeting of May 22, 2019
May 22, 2019
Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy
May 6, 2019
Publication of the 2018 Registration Document
April 8, 2019
Ordinary General Meeting on April 26, 2019
April 5, 2019
Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting
March 25, 2019
Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update
March 12, 2019
Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting
February 13, 2019
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
January 3, 2019
BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results
July 27, 2014
BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions
April 8, 2014
Publication of the 2013 Registration Document
April 8, 2014
BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea
April 2, 2014
BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®
April 1, 2014
BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®
March 31, 2014
Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization
March 19, 2014
Press Release Signup
Subscribe to receive our Press Releases when they come out.
